Karyopharm Therapeutics, Inc. (KPTI)
7.45
+0.31
(+4.34%)
USD |
NASDAQ |
May 19, 14:17
Karyopharm Therapeutics Research and Development Expense (Quarterly) : 33.78M for March 31, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Gilead Sciences, Inc. | 1.354B |
| Catalyst Pharmaceuticals, Inc. | 2.661M |
| Oncolytics Biotech, Inc. | 4.552M |
| Altimmune, Inc. | 16.17M |
| Cellectar Biosciences, Inc. | 3.007M |